Table 5.
Cancer and the Estrogen Plus Progestin Women's Health Initiative[1]
| Estrogen Plus Progestin (HT) (N = 8506) | Placebo (N = 8102) | ||||||
|---|---|---|---|---|---|---|---|
| Cancer | Increased or decreased per 10,000 per year |
Number HT |
Per 10,000/yr HT |
Number placebo |
Per 10,000/yr Placebo |
Percent (%) increased or decreased |
Hazard ratio/95% nCI |
| Invasive breast | 8 increased | 166 | 38 | 124 | 30 | 26 % increased | 1.26/1.00 – 1.59 |
| Endometrial | No difference | 22 | ND | 25 | ND | No increase | 0.83/0.47 – 1.47 |
| Colorectal | 6 decreased | 189 | 10 | 245 | 16 | 37 % decreased | 0.63/0.43 – 0.92 |
| Total | No difference | 502 | ND | 458 | ND | No Increase | 1.03/0.90 – 1.17 |
ND = No data
Note: The HR for invasive breast cancer was 1.24 (95% CI = 1.01-1.54) in the more detailed analysis of the data on invasive breast cancer published in 2003.[34]